New hope for lymphoma patients: experimental drug DS-3201b enters human testing
NCT ID NCT02732275
First seen May 09, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This early-phase study tests an experimental drug called DS-3201b in adults with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to find a safe dose and see how well the drug works. About 100 participants will take part in three parts: dose finding, effectiveness testing, and checking how the drug interacts with other medicines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope National Medical center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Imamura General Hospital
Kagoshima, Kagoshima-ken, 890-0064, Japan
-
Iwate Medical University Hospital
Morioka, Iwate, 020-8505, Japan
-
Kagoshima University Hospital
Kagoshima, Kagoshima-ken, 890-8520, Japan
-
Kumamoto University Hosipital
Kumamoto, Kumamoto, 860-8556, Japan
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Nagasaki University Hospital
Nagasaki, Nagasaki, 852-8501, Japan
-
Nagoya City University Hospital
Nagoya, Aichi-ken, 467-8602, Japan
-
National Cancer Center Hospital
Chūōku, Toyko, 104-0045, Japan
-
National Cancer Center Hospital East
Kahiwa-shi, Chiba, 277-8577, Japan
-
The Institute of Medical Science, The University of Tokyo
Minato-ku, Tokyo, 108-8639, Japan
-
The Ohio State University Wexner Medical Center and James Cancer Hospital
Columbus, Ohio, 43210, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of the Ryukyus Hospital
Nakagami-gun, Okinawa, 903-0215, Japan
-
Weill Cornell Medicine
New York, New York, 10021, United States
-
Yale University
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.